Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib

References

• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi: 10.1016/s0140-6736(12)60150-0
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Chung H, Xu Y, et al. Trends in the prevalence and incidence of ulcerative colitis in Japan and the US. Int J Colorectal Dis. 2023;38(1):135. doi: 10.1007/s00384-023-04417-6.
   PubMed Web of Science ®Google Scholar
• Japan Intractable Diseases Information Center. Ulcerative colitis (Designated Difficult Disease 97) 2022 [cited 2023 February 3]. Available from: https://www.nanbyou.or.jp/entry/62. (in Japanese)
   Google Scholar
• Berends SE, Strik AS, Löwenberg M, et al. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. Clin Pharmacokinet. 2019;58(1):15–37. doi: 10.1007/s40262-018-0676-z.
   PubMed Web of Science ®Google Scholar
• Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9(1):18–27. doi: 10.5009/gnl14226.
   PubMed Web of Science ®Google Scholar
• Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–122. doi: 10.25122/jml-2018-0075.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):870–879. doi: 10.1111/j.1365-2036.2011.04599.x.
   PubMed Web of Science ®Google Scholar
• Hyun HK, Zhang HS, Yu J, et al. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol. 2022;22(1):143. doi: 10.1186/s12876-022-02225-w.
   PubMed Web of Science ®Google Scholar
• Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489–526. doi: 10.1007/s00535-021-01784-1.
   PubMed Web of Science ®Google Scholar
• Jia X, Guo R, Hu Z, et al. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: a meta-analysis. Medicine (Baltimore). 2020;99(44):e22894. doi: 10.1097/md.0000000000022894.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–1302. doi: 10.1111/apt.14030.
   PubMed Web of Science ®Google Scholar
• Vickers AD, Ainsworth C, Mody R, et al. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 2016;11(10):e0165435. doi: 10.1371/journal.pone.0165435.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Meltzer DO, Basu A, Sculpher MJ, et al. Theoretical foundations of cost-effectiveness analysis in health and medicine. In: Neumann PJ, Ganiats TG, Russell LB, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 2016. p. 39–65.
   Google Scholar
• Desai U, Kirson NY, Guglielmo A, et al. Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. J Comp Eff Res. 2021;10(5):393–407. doi: 10.2217/cer-2020-0276.
   PubMed Web of Science ®Google Scholar
• Jairath V, Cohen RD, Loftus EV, et al. Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. BMC Gastroenterol. 2022;22(1):501. doi: 10.1186/s12876-022-02590-6.
   PubMed Web of Science ®Google Scholar
• Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3(1):e000093. doi: 10.1136/bmjgast-2016-000093.
   PubMedGoogle Scholar
• Ruggeri M, Rolli FR. Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis. Glob Reg Health Technol Assess. 2019;6(1) doi: 10.33393/grhta.2019.456.
   Google Scholar
• Ministry of Health Labour and Welfare. Regarding the guidelines and points of caution for the labeling and documentation of pharmaceutical drugs for medical use 2017 [cited 2024 Feburuary 19]. Available from: https://www.pmda.go.jp/files/000218448.pdf (in Japanese)
   Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. doi: 10.1056/nejm198712243172603.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Labour and Welfare. Medical fee information service 2022 [cited 2022 September 3]. Available from: https://shinryohoshu.mhlw.go.jp/shinryohoshu/searchMenu/. (In Japanese)
   Google Scholar
• Ministry of Health Labour and Welfare Science Research Grants Subsidy Policy Research Project for Intractable Diseases. Ulcerative colitis and Crohn’s disease: diagnostic criteria and treatment guidelines 2021 [cited 2022 December 14]. Available from: http://www.ibdjapan.org/pdf/doc15.pdf. (In Japanese)
   Google Scholar
• Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023;5(2):otad009. doi: 10.1093/crocol/otad009.
   PubMedGoogle Scholar
• Ministry of Health Labour and Welfare. About the diagnostic procedure classification (DPC) electronic score table 2022 [cited 2022 April 5]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000198757_00003.html. (In Japanese)
   Google Scholar
• Bank of Japan. List of exchange rates for reporting ministerial ordinance [cited 2023 April 20]. Available from: https://www.boj.or.jp/about/services/tame/tame_rate/syorei/index.htm. (In Japanese)
   Google Scholar
• Loftus EV, Jr., Colombel JF, Takeuchi K, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol. 2022;21(9):2347–2358.e6. doi: 10.1016/j.cgh.2022.11.029.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Sanchez Gonzalez Y, Zhou W, et al. Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2021;15(12):2022–2030. doi: 10.1093/ecco-jcc/jjab099.
   PubMed Web of Science ®Google Scholar
• Toor K, Druyts E, Jansen JP, et al. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ. 2015;18(6):437–446. doi: 10.3111/13696998.2015.1012513.
   PubMed Web of Science ®Google Scholar
• Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. J Med Econ. 2013;16(4):461–467. doi: 10.3111/13696998.2013.775134.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5(5):477–483. doi: 10.1016/j.crohns.2011.06.009.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE), London; 2014.
   Google Scholar
• Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45(6):801–813. doi: 10.1111/apt.13948.
   PubMed Web of Science ®Google Scholar
• Ma C, Sedano R, Almradi A, et al. An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. Gastroenterology. 2021;160(7):2291–2302. doi: 10.1053/j.gastro.2021.02.035.
   PubMed Web of Science ®Google Scholar
• Li K, Marano C, Zhang H, et al. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology. 2020;159(6):2052–2064. doi: 10.1053/j.gastro.2020.08.037.
   PubMed Web of Science ®Google Scholar
• Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282(15):1453–1457. doi: 10.1001/jama.282.15.1453.
   PubMed Web of Science ®Google Scholar